Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943756 | 1.00 | TK1 (0.43) | TK1LMNAALBBLMALDH1A1 | |
| Trichloroethylene SCHEMBL9395208 | 0.93 | TK1 (0.41) | TK1LMNAALBBLMTSHR | |
| SCHEMBL28551951 | 0.87 | LMNA (0.51) | TK1LMNABLMADRA1ATSHR | |
| SCHEMBL28846549 | 0.86 | TK1 (0.35) | TK1 | |
| SCHEMBL8846493 | 0.86 | TK1 (0.50) | TK1LMNABLMADRA1ATSHR | |
| SCHEMBL29364921 | 0.85 | TK1 (0.45) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL135210 | 0.84 | TK1 (0.44) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL16187026 | 0.84 | TK1 (0.44) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL4809531 | 0.84 | TK1 (0.44) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL1490858 | 0.84 | TK1 (0.42) | TK1LMNAALBBLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 977 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4344736-A2 | METHODS FOR CALCULATING BOUNDED DOSE-VOLUME HISTOGRAMS (DVH) FOR EVALUATING A TREATMENT PLAN | RefleXion Medical, Inc. (US) | 2024-04-03 | — | — | EP | claimed |
| US-20230414704-A1 | Compositions Containing a Pharmacophore with Selectivity to Diseased Tissue and Methods of Making Same | SANFORD-BURNHAM MEDICAL DISCOVERY INSTITUTE | 2023-12-28 | — | — | US | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| EP-3218333-B1 | FLUORIDE TRAPPING ARRANGEMENT | GE HEALTHCARE LTD (GB) | 2023-06-07 | — | — | EP | claimed |
| US-11648418-B2 | Systems and methods for biological adaptive radiotherapy | REFLEXION MEDICAL, INC. (US) | 2023-05-16 | — | — | US | claimed |
| US-20230068052-A1 | ELUENT SOLUTION | GE HEALTHCARE LTD (GB) | 2023-03-02 | — | — | US | claimed |
| CN-109154671-B | Radioactivity detection | 赫尔大学 | 2022-10-04 | — | — | CN | claimed |
| CN-109154671-A | RADIOACTIVITY DETECTION | 赫尔大学 | 2019-01-04 | — | — | CN | claimed |
| WO-1999058723-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| CN-1214629-A | Solid immediate release dosage form and process for preparing same | BOEHRINGER MANNHEIM GMBH (DE) | 1999-04-21 | — | — | CN | claimed |
| US-5869097-A | OSMOTIC CAPLET EXIT FOR DELIVERING A PRESELECTED DOSE OF DRUG | ALZA CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| US-5846987-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1998-12-08 | — | — | US | claimed |
| CN-1154111-A | New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | BOEHRINGER MANNHEIM GMBH (DE) | 1997-07-09 | — | — | CN | claimed |
| US-5635523-A | ADMINISTERING MIXTURE OF 5-(N-(N-((N-METHYL-N-((2-ISOPROPYL-4-THIAZOLYL)METHYL) -AMINO)CARBONYL)VALINYL)AMINO)-2-(N-((5-THIAZOLYL)METHOXYCARBONYL)AMINO)-1,6-DIPHENYL-3-HYDROXYHEXANE OR SALT AND REVERSE TRASCRIPTASE INHIBITOR | ABBOTT LABORATORIES (US) | 1997-06-03 | — | — | US | claimed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | claimed |
| CN-1032258-C | Phospholipid derivatives of nucleosides, processes for prepn. thereof and use thereof as antiviral medicaments | BOCHRINGER MANNHEIM GMBH (DE) | 1996-07-10 | — | — | CN | claimed |
| US-5358721-A | Antiviral therapy | ALZA CORPORATION (US) | 1994-10-25 | — | — | US | claimed |
| CN-1059149-A | New nucleoside phospholipid derivant, they method for making and as the application of antiviral | BOEHRINGER MANNHEIM GMBH (DE) | 1992-03-04 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068052-A1 | ELUENT SOLUTION | ABCB11, IPO5, PFAS | TK1 397/4885LMNA 2407/4885ALB 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.